Area of research
Molecular Biology · Surgery
Research interest
Research interests include Melanoma and MAPK Pathways, Eosinophilic Esophagitis, HIV/AIDS drug development and treatment, and Synthesis and biological activity.
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
Disease Burden and Unmet Need in Eosinophilic Esophagitis
Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV
Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.
Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with <i>BRAF</i> V600 mutation-positive (+) metastatic melanoma (MM).
BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM).
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAF<sub>V600/k </sub>mutant advanced or metastatic melanoma (MM).
METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAF<sub>V600E/K </sub>mutant advanced or metastatic melanoma (MM).